Treatment of NSCLC with combination chemoradiotherapy has been associated with the development of ILD (Schweitzer et al, 1995; Reckzeh et al, 1996; Yamada et al, 1998; Robert et al, 1999; Aviram et al, 2001; Komaki et al, 2002) and, as described previously, EGFR-targeted agents may be associated with pulmonary toxicity. This evidence concerns the gene EGFR and interstitial lung disease.